In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
66
Telios Investigative Site
Memphis, Tennessee, United States
RECRUITINGOcular Itching
Ocular itching score will be reported by the subject at 3 timepoints after CAC at Visits 4b , 5, and 6b. Assessments are reported using a 0-4 numerical scale (0 = none and 4 = incapacitating itch with an irresistible urge to rub).
Time frame: 3, 5 and 7 minutes after CAC
Conjunctival Redness
Conjunctival redness score will be evaluated by the investigator at 3 timepoints after CAC at Visits 4b, 5, and 6b. Assessments are completed using a 0-4 numerical scale (0 = none and 4 = extremely severe).
Time frame: 7, 15 and 20 minutes after CAC
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.